Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sairiyo Therapeutics specializes in repurposing and reformulating established natural medicines to improve their clinical utility, focusing on serious infectious diseases and oncology indications. Its lead program PD‑001—a patented enteric-coated oral formulation of cepharanthine—has demonstrated improved bioavailability over generic versions in animal models and has entered the regulatory process for a first-in-human Phase 1 trial targeting viral infectious disease and cancer applications. The company also explores psychedelic compounds for non-neuropsychiatric uses at an early R&D stage.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sairiyo Therapeutics.